Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep;19(3):465-466.
doi: 10.1007/s11302-023-09964-9.

Editorial: Small molecules and biologics for future purinergic therapeutics

Kenneth A Jacobson  1 , Daniela Salvemini  2
Affiliations
Editorial

Editorial: Small molecules and biologics for future purinergic therapeutics

Kenneth A Jacobson et al. Purinergic Signal. 2023 Sep.

Abstract

Receptor agonists and antagonists and other modulators of purinergic signalling have potential as novel therapeutics for a broad range of diseases and conditions. This special issue focuses on compounds or approaches that are either in clinical trials or headed in that direction. It is intended to serve as an up-to-date description of selected efforts to discover and develop new small molecular purinergic drugs.

Keywords: ATP; Adenosine; Drug discovery; G protein-coupled purinergic receptors; Ligand-gated P2X receptors channels; Purinergic signalling.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. IJzerman AP, Jacobson KA, Müller CE, Cronstein BN, Cunha RA. International Union of Basic and Clinical Pharmacology. CXII: Adenosine receptors – a further update. Pharmacol Rev. 2022;74:340–372. doi: 10.1124/pharmrev.121.000445. - DOI - PMC - PubMed
    1. Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F. Update of P2X receptor properties and their pharmacology: IUPHAR Review: 30, Br. J Pharmacol. 2021;178:589–514. - PMC - PubMed
    1. Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B, Miras-Portugal T, Novak I, Schöneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Müller CE. Update of P2Y receptor pharmacology: IUPHAR Review: 27, Br. J Pharmacol. 2020;177:2413–2433. doi: 10.1111/bph.15005. - DOI - PMC - PubMed
    1. Pelleg et al (2023) this issue.
    1. Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2 × 3 and P2 × 2/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol. 2019;176:2279–2291. doi: 10.1111/bph.14677. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources